CClinicalTrials.gg
RecruitingNCT07211763Updated Oct 8, 2025

Comparison of Transcutaneous and Arterial Carbon Dioxide Sampling During Jet Ventilation, a Prospective. Study on Patients Undergoing Percutaneous Liver Tumour Radiofrequency Ablation

An observational study in Liver Ablation and High Frequency Jet Ventilation, sponsored by Sahlgrenska University Hospital. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-08.

Sponsored by Sahlgrenska University Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 6 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

The study aims to compare the readings from two methods of monitoring carbon dioxide levels during jet ventilation when normal end-tidal monitoring is not possible. During jet ventilation it is technically not possible to monitor the levels of carbon dioxide in exhaled air as is the standard in preoperative care. We will compare transcutaneous (through the skin) monitoring to an arterial blood. sample. Both transcutaneous monitoring and arterial monitoring is currently used as the standard for this patient group at our institution. By collecting data prospectively we can evaluate if there. are discrepancies based on monitoring method. All patients will be treated per standard preoperative protocol and only patients consenting to participate will contribute data to the comparison and statistical analysis.

Read the detailed description

During percutaneous radio frequency ablation of liver tumours, jet. ventilation is used to minimise diaphragm movement. By not having conventional ventilation the interventional radiologist have better conditions to perform the treatment and minimising risk damaging adjacent tissue. Jet ventilation does however remove the possibility to monitor end tidal CO2, necessitating alternative monitoring to ensure adequate ventilation. At our institution we use transcutaneous and arterial blood gas monitoring. We aim to collect data on both modalities and compare the values using a "repeat measure Bland-Altmann" analysis.

Study participants will be managed as per normal protocol and the only difference to the non-participators will be their contribution of prospective data for later analysis.

02

Conditions studied

  • Liver Ablation
  • High Frequency Jet Ventilation

Keywords

  • jet ventilation
03

In context

Lead sponsor

Sahlgrenska University Hospital is the lead sponsor of 259 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults undergoing percutaneous RF liver ablation under jet ventilation

Inclusion criteria

  • adult patients undergoing percutaneous RF liver tumour ablation requiring jet ventilation

Exclusion criteria

Exclusion Criteria:

  • disease or condition. not compatible with jet ventilation
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • jet_ventilation

    Other: No Interventions

Interventions

  • OtherNo Interventions

    No intervention, solely data collection

06

What researchers measure

Primary outcomes

  1. Difference in CO2 between TcCO2 and PaCO2

    Time frame: during perioperative management

07

Study locations

1 of 1 sites recruiting
  • Sahlgrenska University Hospital
    Gothenburg, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07211763
Lead sponsor
Sahlgrenska University Hospital
Responsible party
Fredrik Olsen (MD PhD, Sahlgrenska University Hospital) — Principal investigator
First posted
Oct 8, 2025
Start date
Apr 1, 2025
Primary completion
Jun 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Oct 8, 2025

Study contacts

Fredrik Olsen, MD PhD
Contact
fredrik.olsen@vgregion.se
+46 313428169
Carl Hallgren, MD
Contact
carl.hallgren@vgregion.se
+460313430286
Fredrik Olsen, MD PhD
principal investigator · Sahlgrenska University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion